To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)
Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
To assess in adult patients with Idiopathic Pulmonary Fibrosis (IPF) the safety and
tolerability of ascending doses of SAR156597 administered subcutaneously (SC) once weekly
over a 6-week period.
Secondary Objectives:
To assess in adult patients with IPF:
- The pharmacodynamic effects of SAR156597, as measured on pulmonary function tests
(PFTs), pulse oximetry and patient reported outcome and peripheral blood biomarkers.
- The trough plasma concentrations of SAR156597
- The potential immunogenicity of SAR156597.